HRP20120969T1 - Spoj azola - Google Patents
Spoj azola Download PDFInfo
- Publication number
- HRP20120969T1 HRP20120969T1 HRP20120969AT HRP20120969T HRP20120969T1 HR P20120969 T1 HRP20120969 T1 HR P20120969T1 HR P20120969A T HRP20120969A T HR P20120969AT HR P20120969 T HRP20120969 T HR P20120969T HR P20120969 T1 HRP20120969 T1 HR P20120969T1
- Authority
- HR
- Croatia
- Prior art keywords
- carboxylate
- piperidine
- methylpyridin
- acceptable salt
- compound according
- Prior art date
Links
- -1 Azole compound Chemical class 0.000 title claims 12
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- OAQPDTFGBCUPKV-UHFFFAOYSA-N 4-[3-(2-fluorophenyl)-1H-1,2,4-triazol-5-yl]-2-(2-methylpyridin-3-yl)piperidine-1-carboxylic acid Chemical compound CC1=NC=CC=C1C1N(C(O)=O)CCC(C=2NN=C(N=2)C=2C(=CC=CC=2)F)C1 OAQPDTFGBCUPKV-UHFFFAOYSA-N 0.000 claims 2
- NOYXOORGOKRAAZ-UHFFFAOYSA-N 4-[5-(3-fluorophenyl)-1,3-oxazol-2-yl]-2-(2-methylpyridin-3-yl)piperidine-1-carboxylic acid Chemical compound CC1=NC=CC=C1C1N(C(O)=O)CCC(C=2OC(=CN=2)C=2C=C(F)C=CC=2)C1 NOYXOORGOKRAAZ-UHFFFAOYSA-N 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000012752 auxiliary agent Substances 0.000 claims 1
- HMOBXFQCFTZHPG-UHFFFAOYSA-N pyridin-3-yl 4-(3-phenyl-1h-1,2,4-triazol-5-yl)piperidine-1-carboxylate Chemical compound C1CC(C=2NN=C(N=2)C=2C=CC=CC=2)CCN1C(=O)OC1=CC=CN=C1 HMOBXFQCFTZHPG-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (12)
1. Spoj, naznačen time, da je odabran iz skupine koju čine:
piridin-3-il-4-(3-fenil-1H-1,2,4-triazol-5-il)piperidin-1-karboksilat,
6-metilpiridin-3-il-4-[3-(4-fluorofenil)-1H-1,2,4-triazol-5-il]piperidin-1-karboksilat,
6-metilpiridin-3-il-4-[5-(4-fluorofenil)-1,3-oksazol-2-il]piperidin-1-karboksilat,
2,6-dimetilpiridin-3-il-4-[5-(3,4-difluorofenil)-1,2,4-oksadiazol-3-il]piperidin-1-karboksilat,
2-metilpiridin-3-il-4-[3-(2-fluorofenil)-1H-1,2,4-triazol-5-il]piperidin-1-karboksilat,
6-metilpiridin-3-il-4-(3-fenil-1H-pirazol-1-il)piperidin-1-karboksilat,
2-metilpiridin-3-il-4-[5-(3-fluorofenil)-1,3-oksazol-2-il]piperidin-1-karboksilat, i
6-metilpiridin-3-il-4-[4-(4-fluorofenil)-1,3-oksazol-2-il]piperidin-1-karboksilat,
ili njegova farmaceutski prihvatljiva sol.
2. Farmaceutski sastav, naznačen time, da obuhvaća spoj prema zahtjevu 1 ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljivo pomoćno sredstvo.
3. Uporaba spoja prema zahtjevu 1 ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju farmaceutskog sastava za liječenje neuropatskih bolova.
4. Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da se upotrebljava u postupku liječenja neuropatskih bolova.
5. Spoj prema zahtjevu 1, naznačen time, da je to piridin-3-il-4-(3-fenil-1H-1,2,4-triazol-3-il)piperidin-1-karboksilat ili njegova farmaceutski prihvatljiva sol.
6. Spoj prema zahtjevu 1, naznačen time, da je to 6-metilpiridin-3-il-4-[3-(4-fluorofenil)-1H-1,2,4-triazol-5-il]piperidin-1-karboksilat ili njegova farmaceutski prihvatljiva sol.
7. Spoj prema zahtjevu 1, naznačen time, da je to 6-metilpiridin-3-il-4-[5-(4-fluorofenil)-1,3-oksazol-2-il]piperidin-1-karboksilat ili njegova farmaceutski prihvatljiva sol.
8. Spoj prema zahtjevu 1, naznačen time, da je to 2,6-dimetilpiridin-3-il-4-[5-(3,4-difluorofenil)-1,2,4-oksadiazol-3-il]piperidin-1-karboksilat ili njegova farmaceutski prihvatljiva sol.
9. Spoj prema zahtjevu 1, naznačen time, da je to 2-metilpiridin-3-il-4-[3-(2-fluorofenil)-1H-1,2,4-triazol-5-il]piperidin-1-karboksilat ili njegova farmaceutski prihvatljiva sol.
10. Spoj prema zahtjevu 1, naznačen time, da je to 6-metilpiridin-3-il-4-(3-fenil-1H-pirazol-1-il)piperidin-1-karboksilat ili njegova farmaceutski prihvatljiva sol.
11. Spoj prema zahtjevu 1, naznačen time, da je to 2-metilpiridin-3-il-4-[5-(3-fluorofenil)-1,3-oksazol-2-il]piperidin-1-karboksilat ili njegova farmaceutski prihvatljiva sol.
12. Spoj prema zahtjevu 1, naznačen time, da je to 6-metilpiridin-3-il-4-[4-(4-fluorofenil)-1,3-oksazol-2-il]piperidin-1-karboksilat ili njegova farmaceutski prihvatljiva sol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008182251 | 2008-07-14 | ||
PCT/JP2009/062680 WO2010007966A1 (ja) | 2008-07-14 | 2009-07-13 | アゾール化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120969T1 true HRP20120969T1 (hr) | 2012-12-31 |
Family
ID=41550369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120969AT HRP20120969T1 (hr) | 2008-07-14 | 2012-11-28 | Spoj azola |
Country Status (21)
Country | Link |
---|---|
US (1) | US8207199B2 (hr) |
EP (1) | EP2308869B1 (hr) |
JP (1) | JP5423675B2 (hr) |
KR (1) | KR101566051B1 (hr) |
CN (1) | CN102099354B (hr) |
AU (1) | AU2009273105B2 (hr) |
BR (1) | BRPI0915876B1 (hr) |
CA (1) | CA2730793C (hr) |
CY (1) | CY1113439T1 (hr) |
DK (1) | DK2308869T3 (hr) |
ES (1) | ES2393245T3 (hr) |
HR (1) | HRP20120969T1 (hr) |
IL (1) | IL210226A (hr) |
MX (1) | MX2011000415A (hr) |
PL (1) | PL2308869T3 (hr) |
PT (1) | PT2308869E (hr) |
RU (1) | RU2493154C2 (hr) |
SI (1) | SI2308869T1 (hr) |
TW (1) | TWI434842B (hr) |
WO (1) | WO2010007966A1 (hr) |
ZA (1) | ZA201100139B (hr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130150346A1 (en) | 2010-01-08 | 2013-06-13 | Quest Ventures Ltd. | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome |
WO2011123719A2 (en) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
JP2013147430A (ja) * | 2010-04-28 | 2013-08-01 | Astellas Pharma Inc | 夜間頻尿の予防又は治療剤 |
TW201206440A (en) * | 2010-04-28 | 2012-02-16 | Astellas Pharma Inc | Prophylactic or therapeutic agent for diseases associated with pains in urinary organs |
FR2974365B1 (fr) | 2011-04-20 | 2017-08-25 | Centre Nat De La Rech Scient (C N R S) | 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques |
DE102012018115A1 (de) | 2012-09-13 | 2014-03-13 | Matthias Lehr | Aryl-N-(arylalkyl)carbamate als Hemmstoffe der Fatty Acid Amide Hydrolase |
CA2886010A1 (en) * | 2012-10-02 | 2014-04-10 | Sumitomo Dainippon Pharma Co., Ltd. | Imidazole derivative |
DE102013016573A1 (de) | 2013-10-04 | 2015-04-09 | Matthias Lehr | 1-Tetrazolylpropan-2-one als Inhibitoren von cytosolischer Phospholipase A2 und Fatty Acid Amide Hydrolase, insbesondere geeignet zur topischen Anwendung |
CN106632260B (zh) * | 2016-09-29 | 2019-04-26 | 上海天慈生物谷生物工程有限公司 | 一种小分子激酶抑制剂的制备方法 |
EP3529245A4 (en) | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THE LATEST |
CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
CN108409727A (zh) * | 2017-10-25 | 2018-08-17 | 巨德峰 | 一种脂肪酰胺水解酶抑制剂及其制备方法 |
CN112566636A (zh) | 2018-04-25 | 2021-03-26 | 优曼尼蒂治疗公司 | 化合物及其用途 |
CN108912112A (zh) * | 2018-08-14 | 2018-11-30 | 李敬敬 | 一种化合物、制备方法以及其在治疗疼痛中的应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ59398A3 (cs) * | 1996-06-29 | 1998-07-15 | Samjin Pharmaceutical Co., Ltd. | Piperazinové deriváty a způsob jejich přípravy |
CN1326519C (zh) | 2001-12-14 | 2007-07-18 | 诺沃挪第克公司 | 化合物及其降低激素-敏感性脂肪酶活性的用途 |
JP2005516986A (ja) | 2002-02-08 | 2005-06-09 | ブリストル−マイヤーズ スクイブ カンパニー | (オキシム)カルバモイル脂肪酸アミド加水分解酵素インヒビター |
CA2501506C (en) | 2002-10-07 | 2014-02-11 | Daniele Piomelli | Modulation of anxiety through blockade of anandamide hydrolysis |
FR2854633B1 (fr) * | 2003-05-07 | 2005-06-24 | Sanofi Synthelabo | Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
FR2866884B1 (fr) | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique |
TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
MX2007010076A (es) | 2005-02-17 | 2007-10-16 | Astellas Pharma Inc | Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo. |
GB2424955B (en) | 2005-04-09 | 2008-07-16 | Siemens Ag | Flow meter with conductive coating |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
US7541359B2 (en) | 2005-06-30 | 2009-06-02 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
WO2007020888A1 (ja) | 2005-08-12 | 2007-02-22 | Takeda Pharmaceutical Company Limited | 脳・神経細胞保護剤および睡眠障害治療薬 |
-
2009
- 2009-07-10 TW TW098123505A patent/TWI434842B/zh not_active IP Right Cessation
- 2009-07-13 ES ES09797891T patent/ES2393245T3/es active Active
- 2009-07-13 JP JP2010520857A patent/JP5423675B2/ja active Active
- 2009-07-13 CN CN2009801277856A patent/CN102099354B/zh active Active
- 2009-07-13 PT PT97978910T patent/PT2308869E/pt unknown
- 2009-07-13 RU RU2011105151/04A patent/RU2493154C2/ru active
- 2009-07-13 MX MX2011000415A patent/MX2011000415A/es active IP Right Grant
- 2009-07-13 KR KR1020117001096A patent/KR101566051B1/ko active IP Right Grant
- 2009-07-13 EP EP09797891A patent/EP2308869B1/en active Active
- 2009-07-13 PL PL09797891T patent/PL2308869T3/pl unknown
- 2009-07-13 DK DK09797891.0T patent/DK2308869T3/da active
- 2009-07-13 CA CA2730793A patent/CA2730793C/en not_active Expired - Fee Related
- 2009-07-13 US US13/054,057 patent/US8207199B2/en active Active
- 2009-07-13 AU AU2009273105A patent/AU2009273105B2/en not_active Ceased
- 2009-07-13 BR BRPI0915876-6A patent/BRPI0915876B1/pt not_active IP Right Cessation
- 2009-07-13 WO PCT/JP2009/062680 patent/WO2010007966A1/ja active Application Filing
- 2009-07-13 SI SI200930389T patent/SI2308869T1/sl unknown
-
2010
- 2010-12-23 IL IL210226A patent/IL210226A/en not_active IP Right Cessation
-
2011
- 2011-01-05 ZA ZA2011/00139A patent/ZA201100139B/en unknown
-
2012
- 2012-11-28 HR HRP20120969AT patent/HRP20120969T1/hr unknown
- 2012-12-03 CY CY20121101178T patent/CY1113439T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JPWO2010007966A1 (ja) | 2012-01-05 |
SI2308869T1 (sl) | 2012-12-31 |
US20110118311A1 (en) | 2011-05-19 |
TW201014840A (en) | 2010-04-16 |
PT2308869E (pt) | 2012-12-06 |
AU2009273105A1 (en) | 2010-01-21 |
IL210226A (en) | 2014-07-31 |
DK2308869T3 (da) | 2012-10-08 |
ZA201100139B (en) | 2012-03-28 |
IL210226A0 (en) | 2011-03-31 |
CN102099354B (zh) | 2013-07-10 |
WO2010007966A1 (ja) | 2010-01-21 |
BRPI0915876B1 (pt) | 2019-07-09 |
US8207199B2 (en) | 2012-06-26 |
MX2011000415A (es) | 2011-03-15 |
TWI434842B (zh) | 2014-04-21 |
KR20110038671A (ko) | 2011-04-14 |
RU2493154C2 (ru) | 2013-09-20 |
CA2730793A1 (en) | 2010-01-21 |
ES2393245T3 (es) | 2012-12-19 |
CA2730793C (en) | 2014-12-30 |
AU2009273105B2 (en) | 2013-09-05 |
EP2308869B1 (en) | 2012-09-19 |
CN102099354A (zh) | 2011-06-15 |
KR101566051B1 (ko) | 2015-11-04 |
BRPI0915876A2 (pt) | 2015-11-03 |
JP5423675B2 (ja) | 2014-02-19 |
RU2011105151A (ru) | 2012-08-20 |
PL2308869T3 (pl) | 2013-02-28 |
EP2308869A4 (en) | 2011-07-27 |
CY1113439T1 (el) | 2016-06-22 |
EP2308869A1 (en) | 2011-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120969T1 (hr) | Spoj azola | |
FI3362445T3 (fi) | Oksadiatsoliamiinijohdannaisyhdisteitä histonideasetylaasi 6:n inhibiittoreina ja niitä käsittävä farmaseuttinen koostumus | |
HRP20160421T1 (hr) | Derivat azola | |
CL2013000884A1 (es) | El compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino, modulador del factor de crecimiento de fibroblastos (fgf); composicion farmaceutica, util en el tratamiento del cancer. | |
RU2017114355A (ru) | Производные нафтиридина в качестве антагонистов альфа v бета 6 интегрина для лечения, в частности, фиброзных заболеваний | |
NZ594597A (en) | Substituted piperidines as ccr3 antagonists | |
NO20081434L (no) | 5-(fenylisoksazolyletoksy)-triazol-3-yl substituert pyridinsammensetninger for behandling av neurologisk, psykiatrisk eller smerteforstyrrelser | |
SI2947072T1 (sl) | 1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni | |
JP2006500348A5 (hr) | ||
JP2011502958A5 (hr) | ||
PE20090948A1 (es) | Inhibidor de la proteina activadora de la 5-lipoxigenasa (flap) | |
RU2009111113A (ru) | Мидуляторы mglur5 | |
RS53056B (en) | PHARMACEUTICAL PREPARATION CONTAINING (1S) -1,5-ANHYDRO-1- [5- (4-ETHOXYBENZYL) -2-METHOXY-4-METHYLPHENYL] -1-THI-D-GLUCITOL AND METFORMIN AND ITS USE IN THE TREATMENT OF DIABETES | |
MX2010004176A (es) | Derivado de triazol 1,3,5-trisustituido. | |
JP2010505809A5 (hr) | ||
NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni | |
NZ629636A (en) | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions | |
ZA200903578B (en) | Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone | |
NO20052803L (no) | Komplekser av e-2-metoksy-n-(3-{4-(3-metyl-pyridin-3-yloksy)-fenylam ino)-kinazolin-6-yl}-allyl)acetamid, deres fremstillingsmate og bruk | |
EA201270526A1 (ru) | Комбинация | |
EA201490960A1 (ru) | Состав 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамид с немедленным высвобождением | |
EA201270527A1 (ru) | Комбинация | |
JP2016520636A5 (hr) | ||
HRP20171295T1 (hr) | Derivat 6-okso-1,6-dihidro-piridazina za upotrebu za liječenje hepatocelularnog karcinoma (hcc) | |
UY31400A1 (es) | Composiciones farmaceuticas |